Drug Trial Radar · NCT07413341
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Jan 22, 2026
Primary completion
May 1, 2027
Study completion May 30, 2027
Sponsor
- Lead sponsor
- TherornaIndustry
- Sponsor type
- Industry
- First posted
- Feb 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, dose escalation study in patients with relapsed and refractory autoimmune diseases. Study drug, TI-0032-III injection, is composed of lipid nanoparticles (LNPs) targeting T cells that encapsulate circular RNA encoding the CD19 chimeric antigen receptor (CAR), which is a therapeutic biological product. It is clinically intended for the treatment of various relapsed and refractory B cell-related autoimmune diseases, such as systemic lupus erythematosus, sjögren's syndrome, systemic sclerosis, idiopathic inflammatory myositis, and antiphospholipid syndrome.
Conditions
- Systemic Lupus Erythematosus (SLE)
- Sjogren's Syndrome (SS)
- Systemic Sclerosis (SSc)
- Inflammatory Myopathy
- ANCA Associated Systemic Vasculitis
Interventions
TI-0032-III injectionBiological
Multiple doses of TI-0032-III injection will be infused
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety outcomesTime frame: From first dose of TI-0032-III injection until 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.